Indegene

INDGN

NSE

BSE

SectorHealthcare

Loading chart…

Company insights, generated from the most recent coverage.

Q1 FY27 revenue up 39.7% YoY (INR) with strongest sequential growth in 4 years; active clients jumped to 105 from 70, showing broad-based demand beyond top accounts.
Management guides EBITDA margins to recover to 19–20% in H2 FY27, with inflection expected in Q3 — providing clear visibility on profitability normalization.
Post-investor roadshow momentum from Aug 24–25 meetings with global funds like Goldman Sachs driving renewed buying interest.

The Quarter story

The two most recent quarterly results, compared side-by-side.

Indegene expands its client base and recovers profitability, though rising costs and margin compression require monitoring.

Active clients expand from 70 in Q1 FY26 to 105 in Q1 2026-27, broadening the addressable customer base.

EBITDA margin softens from 20.2% in Q1 FY26 to 16.9% in Q1 2026-27, reflecting pricing and cost pressures.

Top 10 client concentration falls from 56.1% in Q1 FY26 to 45.7% in Q1 2026-27, reducing revenue dependency risk.

PAT margin falls from 15.3% in Q1 FY26 to 10.9% in Q1 2026-27, indicating ongoing profitability headwinds.

Profit after tax recovers from ₹797 Cr in Q4 FY26 to ₹1,162 Cr in Q1 2026-27, restoring bottom-line strength.

Employee benefit expenses rise from ₹4,815 Cr in Q1 FY26 to ₹6,591 Cr in Q1 2026-27, weighing on operating costs.

Revenue per employee rises from $70 in Q3 FY26 to $77 in Q1 2026-27, improving workforce productivity.

European revenue share declines from 27.1% in Q1 FY26 to 22.2% in Q1 2026-27, shifting geographic focus.

Voluntary attrition declines from 16.8% in Q1 FY26 to 15.7% in Q1 2026-27, stabilizing talent retention.

Other expenses climb from ₹1,240 Cr in Q1 FY26 to ₹2,298 Cr in Q1 2026-27, increasing operational overhead.

About the company

Indegene Limited is a global provider of digital-led commercialization services for the life sciences industry. The company offers solutions in analytics, technology, and commercial, medical, regulatory, and safety services to biopharmaceutical, emerging biotech, and medical devices companies. Indegene operates through four main segments: Enterprise Commercial Solutions, Omnichannel Activation, Enterprise Medical Solutions, and Others. These segments assist with digital marketing operations, last-mile promotion optimization, regulatory and medical operations consolidation, and clinical solutions and consultancy services. The company has made several acquisitions to expand its capabilities, including Encima Group, DT Associates, Cult Health, and Trilogy Writing & Consulting GmbH. In 2023, Indegene launched Invisage, an AI-enabled hybrid omnichannel sales and marketing platform. The company completed a public issue in May 2024, raising funds through a fresh issue and offer for sale.

In the news